These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24767731)

  • 1. Ipilimumab in patients with cancer and the management of dermatologic adverse events.
    Lacouture ME; Wolchok JD; Yosipovitch G; Kähler KC; Busam KJ; Hauschild A
    J Am Acad Dermatol; 2014 Jul; 71(1):161-9. PubMed ID: 24767731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
    Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
    Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
    Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
    PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
    Minkis K; Garden BC; Wu S; Pulitzer MP; Lacouture ME
    J Am Acad Dermatol; 2013 Sep; 69(3):e121-8. PubMed ID: 23357570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
    Lipson EJ; Drake CG
    Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
    J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
    PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab for advanced melanoma: a pharmacologic perspective.
    Trinh VA; Hagen B
    J Oncol Pharm Pract; 2013 Sep; 19(3):195-201. PubMed ID: 23047236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
    Dika E; Ravaioli GM; Fanti PA; Piraccini BM; Lambertini M; Chessa MA; Baraldi C; Ribero S; Andrea A; Melotti B; Patrizi A
    Eur J Dermatol; 2017 Jun; 27(3):266-270. PubMed ID: 28524050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab: in previously treated patients with advanced melanoma.
    Sanford M
    BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin Reactions to Immune Checkpoint Inhibitors.
    Patel AB; Pacha O
    Adv Exp Med Biol; 2018; 995():117-129. PubMed ID: 30539508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.